Considerations in the development of drugs to treat sarcopenia

Journal of the American Geriatrics Society

Volumn 59, Issue 3, 2011, Pages 530-535

  Brass, Eric P ^a   Sietsema, Kathy E ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Drug development; Exercise; Physical performance; Sarcopenia

Indexed keywords

NEW DRUG;

COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FALLING; FOOD AND DRUG ADMINISTRATION; FRACTURE; FUNCTIONAL ASSESSMENT; HEALTH CARE; HEALTH STATUS; HUMAN; MEDICAL DECISION MAKING; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE STRENGTH; PHYSICAL PERFORMANCE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; WALKING;

ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HUMANS; RISK FACTORS; SARCOPENIA; UNITED STATES;

EID: 79952554785     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.03285.x     Document Type: Review

References (30)

1. Abellan van Kan G, Andre E, Bischoff Ferrari HA et al. Carla task force on sarcopenia: Propositions for clinical trials. J Nutr Health Aging 2009;13:700-707.
2. Rosenberg I. Summary comments. Am J Clin Nutr 1989;50:1231-1233. (Pubitemid 19282798)
3. Doherty TJ. Invited review: Aging and sarcopenia. J Appl Physiol 2003;95:1717-1727. (Pubitemid 37169320)
4. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56A:M146-M156. (Pubitemid 32187141)
5. Visser M. Towards a definition of sarcopenia - results from epidemiologic studies. J Nutr Health Aging 2009;13:713-716.
6. Cawthon PM, Fox KM, Gandra SR et al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? J Am Geriatr Soc 2009;57:1411-1419.
7. Moreland JD, Richardson JA, Goldsmith CH et al. Muscle weakness and falls in older adults: A systematic review and meta-analysis. J Am Geriatr Soc 2004;52:1121-1129. (Pubitemid 38869071)
8. Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767-773.
9. Visser M, Goodpaster BH, Kritchevsky SB et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 2005;60A:324-333. (Pubitemid 40628797)
10. Cesari M, Pahor M, Lauretani F et al. Skeletal muscle and mortality results from the InCHIANTI Study. J Gerontol A Biol Sci Med Sci 2009;64A:377-384.
11. Evans WJ. Skeletal muscle loss: Cachexia, sarcopenia, and inactivity. Am J Clin Nutr 2010;91:1123S-1127S.
12. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 2005;24:67-78. (Pubitemid 40173935)
13. Cumming RG, Ivers R, Clemson L et al. Improving vision to prevent falls in frail older people: A randomized trial. J Am Geriatr Soc 2007;55:175-181. (Pubitemid 46184391)
14. Lord SR, Castell S, Corcoran J et al. The effect of group exercise on physical functioning and falls in frail older people living in retirement villages: A randomized, controlled trial. J Am Geriatr Soc 2003;51:1685-1692. (Pubitemid 37543353)
15. Cummings SR, Nevitt MC, Kidd S. Forgetting falls. The limited accuracy of recall of falls in the elderly. J Am Geriatr Soc 1988;36:613-616.
16. Chen JS, Sambrook PN, Simpson JM et al. A selection strategy was developed for fracture reduction programs in frail older people. J Clin Epidemiol 2010;63:679-685.
17. Colman EG. The Food and Drug Administration's osteoporosis guidance document: Past, present, and future. J Bone Miner Res 2003;18:1125-1128. (Pubitemid 37294953)
18. Working Group on Functional Outcome Measures for Clinical Trials Functional outcomes for clinical trials in frail older persons: Time to be moving. J Gerontol A Biol Sci Med Sci 2008;63A:160-164.
19. Abellan van Kan G, Rolland Y, Andrieu S et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging 2009;13:881-889.
20. Guralnik JM, Ferrucci L, Pieper CF et al. Lower extremity function and subsequent disability: Consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci 2000;55A:M221-M231. (Pubitemid 30257618)
21. Masel MC, Graham JE, Reistetter TA et al. Frailty and health related quality of life in older Mexican Americans. Health Qual Life Outcomes 2009;7:70.
22. U.S. Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims [on-line]. Available at http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf Accessed March 31, 2010.
23. Perret-Guillaume C, Briancon S, Guillemin F et al. Which generic health related quality of life questionnaire should be used in older inpatients: Comparison of the Duke health profile and the MOS short-form SF-36? J Nutr Health Aging 2010;14:325-331.
24. Stadnyk K, Calder J, Rockwood K. Testing the measurement properties of the short form-36 Health Survey in a frail elderly population. J Clin Epidemiol 1998;51:827-835. (Pubitemid 28470124)
25. McDermott MM, Ferrucci L, Guralnik J et al. Pathophysiological changes in calf muscle predict mobility loss at 2-year follow-up in men and women with peripheral arterial disease. Circulation 2009;120:1048-1055.
26. Schols AM, Soeters PB, Dingemans AM et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993;147:1151-1156. (Pubitemid 23149871)
27. Nicoletti I, Cicoira M, Zanolla L et al. Skeletal muscle abnormalities in chronic heart failure patients: Relation to exercise capacity and therapeutic implications. Congest Heart Fail 2003;9:148-154. (Pubitemid 37081528)
28. Ohkawa S, Odamaki M, Ikegaya Net al. Association of age with muscle mass, fat mass and fat distribution in non-diabetic haemodialysis patients. Nephrol Dial Transplant 2005;20:945-951.
29. Brass EP, Lewis RJ, Lipicky R et al. Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular risk. Clin Pharmacol Ther 2006;79:165-172.
30. Fleming TR. Current issues in non-inferiority trials. Stat Med 2008;27:317-332. (Pubitemid 351227869)